Is Milestone Pharmaceuticals Stock a Good Investment?
Milestone Pharmaceuticals Investment Advice | MIST |
- Examine Milestone Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Milestone Pharmaceuticals' leadership team and their track record. Good management can help Milestone Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Milestone Pharmaceuticals' business and its evolving consumer preferences.
- Compare Milestone Pharmaceuticals' performance and market position to its competitors. Analyze how Milestone Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Milestone Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Milestone Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Milestone Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Milestone Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Milestone Pharmaceuticals Stock
Researching Milestone Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 57.0% of the company shares are owned by institutional investors. The book value of Milestone Pharmaceuticals was now reported as 0.39. The company recorded a loss per share of 0.8. Milestone Pharmaceuticals had not issued any dividends in recent years. The entity had 1-1 split on the 24th of March 2020.
To determine if Milestone Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Milestone Pharmaceuticals' research are outlined below:
| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (59.69 M) with profit before overhead, payroll, taxes, and interest of 5 M. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (46.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Milestone Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference |
Milestone Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Milestone Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Milestone Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Milestone Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Milestone Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.16 | -0.1426 | 0.0174 | 10 | ||
2022-03-24 | 2021-12-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2021-11-12 | 2021-09-30 | -0.38 | -0.34 | 0.04 | 10 | ||
2024-08-08 | 2024-06-30 | -0.19 | -0.14 | 0.05 | 26 | ||
2024-05-13 | 2024-03-31 | -0.26 | -0.21 | 0.05 | 19 | ||
2023-05-11 | 2023-03-31 | -0.4 | -0.35 | 0.05 | 12 | ||
2022-05-12 | 2022-03-31 | -0.39 | -0.33 | 0.06 | 15 | ||
2020-08-12 | 2020-06-30 | -0.47 | -0.53 | -0.06 | 12 |
Know Milestone Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Milestone Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Milestone Pharmaceuticals backward and forwards among themselves. Milestone Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Milestone Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stonepine Capital Management Llc | 2024-06-30 | 1.2 M | Bml Capital Management Llc | 2024-09-30 | 1.1 M | Ikarian Capital, Llc | 2024-09-30 | 466 K | Altium Capital Management, Lp | 2024-09-30 | 440 K | Boxer Capital Llc | 2024-09-30 | 309 K | Envestnet Asset Management Inc | 310000-09-30 | 70.6 K | Ancora Advisors Llc | 2024-06-30 | 60 K | Squarepoint Ops Llc | 2024-06-30 | 54.7 K | Atria Investments Llc | 2024-09-30 | 40.4 K | Blackrock Inc | 2024-06-30 | 5 M | Rtw Investments, Llc | 2024-06-30 | 3.3 M |
Milestone Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 98.66 M.Market Cap |
|
Milestone Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (0.90) | (0.94) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (3.56) | (3.38) |
Determining Milestone Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Milestone Pharmaceuticals is a good buy. For example, gross profit margin measures Milestone Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Milestone Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Milestone Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Milestone Pharmaceuticals. Check Milestone Pharmaceuticals' Beneish M Score to see the likelihood of Milestone Pharmaceuticals' management manipulating its earnings.
Evaluate Milestone Pharmaceuticals' management efficiency
Milestone Pharmaceuticals has return on total asset (ROA) of (0.3309) % which means that it has lost $0.3309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3375) %, meaning that it created substantial loss on money invested by shareholders. Milestone Pharmaceuticals' management efficiency ratios could be used to measure how well Milestone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2024. Return On Capital Employed is likely to drop to -0.94 in 2024. At this time, Milestone Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 468 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 6.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.39 | 0.37 | |
| Tangible Book Value Per Share | 0.39 | 0.37 | |
| Enterprise Value Over EBITDA | (1.93) | (2.03) | |
| Price Book Value Ratio | 4.28 | 4.49 | |
| Enterprise Value Multiple | (1.93) | (2.03) | |
| Price Fair Value | 4.28 | 4.49 | |
| Enterprise Value | 109.8 M | 207.7 M |
Leadership at Milestone Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.729 |
Basic technical analysis of Milestone Stock
As of the 28th of November, Milestone Pharmaceuticals secures the Downside Deviation of 2.16, mean deviation of 1.9, and Risk Adjusted Performance of 0.1093. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Milestone Pharmaceuticals, as well as the relationship between them.Milestone Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Milestone Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Milestone Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Milestone Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Milestone Pharmaceuticals' Outstanding Corporate Bonds
Milestone Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Milestone Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Milestone bonds can be classified according to their maturity, which is the date when Milestone Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Milestone Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Milestone Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1093 | |||
| Market Risk Adjusted Performance | 0.3525 | |||
| Mean Deviation | 1.9 | |||
| Semi Deviation | 1.61 | |||
| Downside Deviation | 2.16 | |||
| Coefficient Of Variation | 750.28 | |||
| Standard Deviation | 2.92 | |||
| Variance | 8.54 | |||
| Information Ratio | 0.0887 | |||
| Jensen Alpha | 0.2461 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.1202 | |||
| Treynor Ratio | 0.3425 | |||
| Maximum Drawdown | 18.66 | |||
| Value At Risk | (2.11) | |||
| Potential Upside | 7.19 | |||
| Downside Variance | 4.65 | |||
| Semi Variance | 2.58 | |||
| Expected Short fall | (2.80) | |||
| Skewness | 1.84 | |||
| Kurtosis | 5.3 |
| Risk Adjusted Performance | 0.1093 | |||
| Market Risk Adjusted Performance | 0.3525 | |||
| Mean Deviation | 1.9 | |||
| Semi Deviation | 1.61 | |||
| Downside Deviation | 2.16 | |||
| Coefficient Of Variation | 750.28 | |||
| Standard Deviation | 2.92 | |||
| Variance | 8.54 | |||
| Information Ratio | 0.0887 | |||
| Jensen Alpha | 0.2461 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.1202 | |||
| Treynor Ratio | 0.3425 | |||
| Maximum Drawdown | 18.66 | |||
| Value At Risk | (2.11) | |||
| Potential Upside | 7.19 | |||
| Downside Variance | 4.65 | |||
| Semi Variance | 2.58 | |||
| Expected Short fall | (2.80) | |||
| Skewness | 1.84 | |||
| Kurtosis | 5.3 |
Consider Milestone Pharmaceuticals' intraday indicators
Milestone Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Milestone Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Milestone Pharmaceuticals time-series forecasting models is one of many Milestone Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Milestone Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Milestone Stock media impact
Far too much social signal, news, headlines, and media speculation about Milestone Pharmaceuticals that are available to investors today. That information is available publicly through Milestone media outlets and privately through word of mouth or via Milestone internal channels. However, regardless of the origin, that massive amount of Milestone data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Milestone Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Milestone Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Milestone Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Milestone Pharmaceuticals alpha.
Milestone Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Milestone Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Milestone Pharmaceuticals Corporate Management
| Anita Holz | VP Affairs | Profile | |
| Guy Rousseau | SVP Management | Profile | |
| FACC FAHA | Chief Board | Profile | |
| Jeffrey Nelson | Chief Officer | Profile | |
| Roshan Girglani | Vice Marketing | Profile |
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.